Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst John Newman maintains a Buy rating on Seres Therapeutics (NASDAQ:MCRB) and keeps the price target at $10.
August 14, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst John Newman maintains a Buy rating on Seres Therapeutics and keeps the price target at $10.
The reaffirmation of a Buy rating and a $10 price target by Canaccord Genuity is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100